MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis.

about

MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis.

Item

http://www.wikidata.org/entity/Q55491411

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

MET alterations detected in bl ...... metastases and poor prognosis.

@en

MET alterations detected in bl ...... metastases and poor prognosis.

@nl

type

Item

label

MET alterations detected in bl ...... metastases and poor prognosis.

@en

MET alterations detected in bl ...... metastases and poor prognosis.

@nl

prefLabel

MET alterations detected in bl ...... metastases and poor prognosis.

@en

MET alterations detected in bl ...... metastases and poor prognosis.

@nl

P1476

MET alterations detected in bl ...... metastases and poor prognosis.

@en

P2093

Denis L Fontes Jardim

http://www.w3.org/2001/XMLSchema#string

Mandakini Mohindra

http://www.w3.org/2001/XMLSchema#string

Sadakatsu Ikeda

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product

Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Met, metastasis, motility and more

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.

Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy

Targeting MET Amplification as a New Oncogenic Driver.

Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors.

Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.

P2888

s13045-018-0610-8

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13045-018-0610-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Razelle Kurzrock

Maria Schwaederle

P577

2018-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104385496

http://www.w3.org/2001/XMLSchema#string

P698

29866143

http://www.w3.org/2001/XMLSchema#string

P932

5987577

http://www.w3.org/2001/XMLSchema#string